Objectives, Anecdotal reports of increased libido and sexual function
in patients taking trazodone have led to its empirical use in patients
with erectile dysfunction. A retrospective review of patient-reported
responses to trazodone was performed to outline the efficacy and side
-effect profile of this agent. Methods. Between 1989 and 1994, 182 pat
ients were placed on oral trazodone as empirical therapy for erectile
dysfunction. Patients ranged in age from 26 to 85 years, with a mean o
f 60 years. Patients were evaluated before receiving trazodone with a
thorough medical history and physical examination. Known risk factors
for erectile dysfunction were assigned based on historical information
and the findings of the examination. Patients received trazodone for
at least 2 consecutive months, with daily doses starting at 25 mg. Res
ults. One hundred twenty-seven patients were available for follow-up b
y a standardized questionnaire regarding perceived improvement in erec
tile function, sexual function, and side effects. In patients less tha
n 60 years of age, with no known risk factors for erectile dysfunction
, 21 of 27 (78%) showed significant improvement in erectile ability, S
mokers and patients older than 60 years with a history of significant
peripheral vascular disease responded poorly to trazodone therapy. The
duration of erectile dysfunction was inversely related to a response
to trazodone. Of patients with a duration of impotence less than 12 mo
nths, 48% reported a positive response. Only 16% of patients with dura
tion of erectile dysfunction greater than 60 months reported improveme
nt in erections and sexual function. Trazodone was well tolerated by t
his population, with 62% reporting no side effects. Conclusions. Despi
te the limitations of a nonrandomized, retrospective study, trazodone
appears to benefit younger patients with erectile dysfunction with few
known risk factors. A prospective, placebo-controlled trial is needed
to confirm the observations of this pilot study.